|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
Journal of Cell Science, Vol 108, Issue 2 519-527, Copyright © 1995 by Company of Biologists
JOURNAL ARTICLES |
PL Jones, N Boudreau, CA Myers, HP Erickson and MJ Bissell
Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720, USA.
The physiological role of tenascin in vivo has remained obscure. Although tenascin is regulated in a stage and tissue-dependent manner, knock-out mice appear normal. When tenascin expression was examined in the normal adult mouse mammary gland, little or none was present during lactation, when epithelial cells actively synthesize and secrete milk proteins in an extracellular matrix/lactogenic hormone-dependent manner. In contrast, tenascin was prominently expressed during involution, a stage characterized by the degradation of the extracellular matrix and the subsequent loss of milk production. Studies with mammary cell lines indicated that tenascin expression was high on plastic, but was suppressed in the presence of the laminin-rich, Engelbreth-Holm-Swarm (EHS) tumour biomatrix. When exogenous tenascin was added together with EHS to mammary epithelial cells, beta-casein protein synthesis and steady-state mRNA levels were inhibited in a concentration-dependent manner. Moreover, this inhibition by tenascin could be segregated from its effects on cell morphology. Using two beta-casein promoter constructs attached to the chloramphenicol acetyltransferase reporter gene we showed that tenascin selectively suppressed extracellular matrix/prolactin-dependent transcription of the beta-casein gene in three-dimensional cultures. Finally, we mapped the active regions within the fibronectin type III repeat region of the tenascin molecule that are capable of inhibiting beta-casein protein synthesis. Our data are consistent with a model where both the loss of a laminin-rich basement membrane by extracellular matrix-degrading enzymes and the induction of tenascin contribute to the loss of tissue-specific gene expression and thus the involuting process.
This article has been cited by other articles:
|
|
 |
|
  S. G. Hakim, H. Kosmehl, I. Lauer, R. Nadrowitz, T. Wedel, and P. Sieg A Comparative Study on the Protection Profile of Lidocaine, Amifostine, and Pilocarpin on the Parotid Gland during Radiotherapy Cancer Res., November 15, 2005; 65(22): 10486 - 10493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Philp, S. S. Chen, W. Fitzgerald, J. Orenstein, L. Margolis, and H. K. Kleinman Complex Extracellular Matrices Promote Tissue-Specific Stem Cell Differentiation Stem Cells, February 1, 2005; 23(2): 288 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Chen, F.-E Mo, and L. F. Lau The Angiogenic Factor Cyr61 Activates a Genetic Program for Wound Healing in Human Skin Fibroblasts J. Biol. Chem., December 7, 2001; 276(50): 47329 - 47337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Puente Navazo, D. Valmori, and C. Ruegg The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production J. Immunol., December 1, 2001; 167(11): 6431 - 6440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schenk, R. Chiquet-Ehrismann, and E. J. Battegay The Fibrinogen Globe of Tenascin-C Promotes Basic Fibroblast Growth Factor-induced Endothelial Cell Elongation Mol. Biol. Cell, September 1, 1999; 10(9): 2933 - 2943. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Jones, F. Jones, B Zhou, and M Rabinovitch Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element J. Cell Sci., January 2, 1999; 112(4): 435 - 445. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Thomasset, A. Lochter, C. J. Sympson, L. R. Lund, D. R. Williams, O. Behrendtsen, Z. Werb, and M. J. Bissell Expression of Autoactivated Stromelysin-1 in Mammary Glands of Transgenic Mice Leads to a Reactive Stroma During Early Development Am. J. Pathol., August 1, 1998; 153(2): 457 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, S. L. Young, and J. C. McIntosh Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 1998; 274(6): L1049 - L1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Phillips, L. Krushel, and K. Crossin Domains of tenascin involved in glioma migration J. Cell Sci., January 4, 1998; 111(8): 1095 - 1104. [Abstract] [PDF]
|
|
|
|
 |
|
 P. L. Jones, J. Crack, and M. Rabinovitch Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the alpha vbeta 3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth J. Cell Biol., October 6, 1997; 139(1): 279 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Jones and M. Rabinovitch Tenascin-C Is Induced With Progressive Pulmonary Vascular Disease in Rats and Is Functionally Related to Increased Smooth Muscle Cell Proliferation Circ. Res., December 1, 1996; 79(6): 1131 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
E. Mackie and S Ramsey Modulation of osteoblast behaviour by tenascin J. Cell Sci., January 6, 1996; 109(6): 1597 - 1604. [Abstract] [PDF]
|
|
